News MSD's TL1A drug tulisokibart delivers in pivotal IBD trial MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.
R&D Sponsored Solution Spotlight: Inventus Control (Mobile Device Manageme... Through Inventus Control, Inventus delivers a dedicated Mobile Device Management (MDM) platform for the life sciences sector.
News Boehringer advances duo for aggressive cancers into phase 3 Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.
R&D Clinical Trials Round-Up: March and April 2026 March and April offered no shortage of talking points for the clinical trials community.
News Poolbeg expects first data for CRS drug in the summer A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.
Sales & Marketing Sponsored Solution Spotlight: IQVIA CTFS Site Payments IQVIA Clinical Trial Financial Suite (CTFS) is a next-generation platform designed to modernise clinical trial financial operations.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.